Seagen
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 11 disclosed transactions, Seagen concentrates its licensing activity in Oncology, Neurology, and Other. Seagen pays a 1.48x premium over market median. Their most common deal structure is License, with an average disclosed value of $2.0B. Most recent activity: 2023.
Pipeline coverage & gaps
Seagen has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $128M | $1.5B |
| Collaboration | 2 | $60M | $3.5B |
| Co Development | 2 | $543M | $1.5B |
| Option | 1 | $60M | $3.5B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | HBM9033 | HBM Holdings Limited (Nona Biosciences) | solid_tumor | preclinical | $53M | $1.1B |
| 2023 | Degrader-Antibody Conjugate (DAC) programs | Nurix Therapeutics | multiple oncology indications | discovery | $60M | $3.5B |
| 2023 | bladder | Astellas Pharma | bladder | approved | — | $800M |
| 2023 | E3 ligase-targeted cancer therapies | Nurix | multiple oncology indications | unknown | $60M | $3.5B |
| 2023 | targeted protein degradation multi-program collaboration | Nurix Therapeutics | oncology | discovery | $60M | $3.5B |
| 2022 | SGN-EGFRd2 | LAVA Therapeutics, N.V. | advanced EGFR-expressing solid tumors | preclinical | $50M | $700M |
| 2021 | disitamab vedotin | RemeGen Co., Ltd. | gastric cancer, urothelial carcinoma, breast cancer, other HER2-expressing cancers | approved | $200M | $2.6B |
| 2021 | RC48 (disitamab vedotin) | RemeGen | HER2-expressing cancers | phase_1 | $200M | $2.6B |
| 2021 | SV2A | Axsome Therapeutics | OCD | discovery | $13M | $154M |
| 2020 | GABA-A-stat | Karuna Therapeutics | Migraine | approved | $543M | $2.1B |
| 2017 | sacituzumab govitecan | Immunomedics | triple negative breast cancer | phase_2 | $250M | $1.9B |
How this is computed
For each Seagen deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.479, clamped to [0.7, 1.5].